Search

In January 23-year-old Jake Ternent became the first person with an inherited sight loss condition to be treated in the UK with Luxturna (voretigene neparvovec) for Leber congenital amaurosis (LCA).

• News
• Leber congenital amaurosis (LCA)

Fundraising for Retina UK means a lot to me - both my dad and my nephew have been affected by inherited sight-loss, and I've seen first-hand the incredible work this charity does.

• Case study - supporter
• Written

The latest research news piece from Retina UK.

• News
• Stargardt disease

The Spring 2023 edition of the Retina UK newsletter, Look Forward, which includes articles about our upcoming events, research updates and more.

• Look Forward
• Audio
• Written

Our Scientific & Medical Advisory Board (SMAB) advises our Board of Trustees in order that they can approve grants for research projects.

We can provide all the support your organisation needs to work with us; from ideas to practical support and materials. The Retina UK team will help your contribution be as fun and rewarding as possible.

Roger has retinitis pigmentosa, as do his son, mother and grandfather. He was officially diagnosed aged 16.

• Trustee
• Written

Our Keynote speaker will be Mr Kanmin Xue. Mr Xue is a Consultant Vitreo-retinal Surgeon at the John Radcliffe Hospital and Wellcome Trust clinician scientist fellow at the University of Oxford where he leads the Retinal Disease and Repair Group.

• Information event
• Audio
• Written

Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.

• News
• Retinitis pigmentosa

Prof Mariya Moosajee at Moorfields Eye Hospital has asked us to share the message below about the clinical trial she is running. This trial is for a treatment that targets a particular section of the USH2A gene.

• News
• Usher syndrome